141 results on '"Nacey, John N."'
Search Results
2. PSA testing in detection and treatment of prostate cancer
3. Relapse patterns after low-dose-rate prostate brachytherapy
4. Patterns of failure after iodine-125 seed implantation for prostate cancer
5. Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases
6. Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour de-differentiation
7. Gleason and Fuhrman no longer make the grade
8. Active surveillance for prostate cancer: the role of the pathologist
9. Effective maybe, but is it cost-effective? A reply
10. Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastases
11. Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men
12. Prostate cancer: the new evidence base for diagnosis and treatment
13. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype
14. Differences in prostate disease symptoms and visits to the general practitioner among three ethnic groups in New Zealand
15. Assessment of ethnic variation in serum levels of total, complexed and free prostate specific antigen. Comparison of Maori, Pacific Island and New Zealand European populations
16. Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR)
17. Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR)
18. Broadsheet number 45: Thin core biopsy of prostate
19. Familial cystic nephroma and pleuropulmonary blastoma
20. Nucleolar organizer regions and prognosis in renal cell carcinoma
21. A prospective audit of the 10-year outcomes from low dose-rate brachytherapy for early stage prostate cancer.
22. Reply: Gleason and Fuhrman no longer make the grade
23. Gleason and Fuhrman no longer make the grade
24. Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour de‐differentiation
25. Proteins from formalin-fixed paraffin-embedded prostate cancer sections that predict the risk of metastatic disease
26. Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastases
27. RENAL CELL CARCINOMA II. HISTOLOGICAL INDICATORS OF PROGNOSIS
28. The evolution of collagen expression in sarcomatoid renal cell carcinoma
29. Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000
30. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia
31. A comparison of cancer statistics in New Zealand and Australia: 1996-2007.
32. Analysis of the prevalence of voiding symptoms in maori, pacific island, and caucasian new zealand men
33. THE EFFECT OF FINASTERIDE ON PROSTATE VOLUME, URINARY FLOW RATE AND SYMPTOM SCORE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
34. Renal cell carcinoma in New Zealand: A national survival study
35. Proliferating cell nuclear antigen (PCNA) expression as a prognostic indicator for renal cell carcinoma: Comparison with tumour grade, mitotic index, and silver-staining nucleolar organizer region numbers
36. Letters to the editor
37. Giant Cystic Nephroma in An Adult
38. Diagnosis of renal oncocytoma
39. Testicular Germ Cell Tumor with Pineal Metastases
40. THE EFFECT OF FINASTERIDE ON PROSTATE VOLUME, URINARY FLOW RATE AND SYMPTOM SCORE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA.
41. The Assessment of Urinary Catheter Toxicity Using Cell Cultures: Validation by Comparison with an Animal Model
42. The Assessment of Catheter-Induced Urethritis Using an Experimental Dog Model
43. An Improved Method for the Preparation and Culture of Urothelial Cells
44. Histopathologic prognostic factors in renal cell carcinoma
45. PSA testing--who should decide when it is performed?
46. Elevated serum prostate-specific antigen levels and public health implications in three New Zealand ethnic groups: European, Maori, and Pacific Island men
47. Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure.
48. Revised status of PSA testing in the early detection and treatment of prostate cancer.
49. Environmental exposure to trace elements and prostate cancer in three New Zealand ethnic groups.
50. Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.